iHub Stent-Graft for Iliac Artery Aneurysms: Safety, Performance, and Effectiveness Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorArcho Medical S.A

About this trial

The goal of this clinical trial is to evaluate the safety, performance, and Preliminary effectiveness of the iHub endoprosthesis system in treating iliac artery aneurysms in adult patients requiring endovascular repair. The study population includes both male and female adults over 18 years of age who meet the inclusion criteria for endovascular treatment of iliac artery aneurysms.

The main questions it aims to answer are:

Is the iHub stent-graft system safe for use in patients with iliac artery aneurysms? Does the iHub system demonstrate adequate technical performance and sustained patency over a 12-month follow-up period? Participants will undergo a minimally invasive endovascular procedure to implant the iHub endoprosthesis system. The device is designed to preserve internal iliac artery flow while excluding the aneurysmal segment.

Participants will:

Undergo pre-screening evaluations including clinical examination, laboratory tests, and imaging (CT angiography and ultrasound).

Undergo endovascular implantation of the iHub device. Attend follow-up visits at 30, 90, 180, and 360 days post-implant to assess clinical outcomes and device performance.

Eligibility criteria

Qualifiers

Common iliac artery aneurysm ≥ 25 mm in diameter;

Aneurysm growth of 5 mm or more within the last six months;

Maximum aneurysm diameter exceeds 1 to 1.5 times the normal arterial segment diameter, that is ≥ 25 mm maximum diameter;

Saccular aneurysm greater than 20 mm;

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Endovascular Iliac Branch Stent-Graft Implantation

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators